Stock data
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB) reported revenue of US$0.00M and net income of -US$19.42M for fiscal 2026. The figures below come from the company's SEC filings.
Annual results
Data as of 2026-04-30
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | US$0.00M | — | -US$6.85M | -US$19.42M | — |
| 2025 | US$0.00M | — | -US$4.38M | US$30.66M | — |
| 2024 | US$0.00M | — | -US$8.52M | US$0.33M | — |
| 2023 | US$0.00M | — | -US$6.46M | -US$4.32M | — |
| 2022 | US$0.00M | — | -US$4.39M | -US$4.24M | — |
Quarterly results
Data as of 2026-07-31
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-07-31 | US$0.00M | -US$5.08M | — |
| 2026-04-30 | US$0.00M | -US$4.39M | — |
| 2026-01-31 | US$0.00M | US$0.75M | — |
| 2025-10-31 | US$0.00M | -US$7.42M | — |
| 2025-07-31 | US$0.00M | -US$8.36M | — |
| 2025-04-30 | US$0.00M | US$11.75M | — |
| 2025-01-31 | US$0.00M | -US$3.05M | — |
| 2024-10-31 | US$0.00M | -US$1.47M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.